Est. 2001·3,000+ placements · six offices · four regions
M&A Activitycurated sourcedetected 2026-03-24 · confidence 95%

Last updated

Gilead Sciences: M&A Activity

Gilead Sciences agreed to acquire Ouro Medicines for up to $2.18 billion, gaining rights to antibody drug licensed from China's Keymed Biosciences

Source: South China Morning Post - Business

Who
Gilead Sciences · Biotech & Pharma · China
What happened
Gilead Sciences agreed to acquire Ouro Medicines for up to $2.18 billion, gaining rights to antibody drug licensed from China's Keymed Biosciences
When
2026-03-24
So what
Gilead's acquisition of Ouro is structurally a China-origin asset play dressed as a US biotech deal.

The leadership read

Gilead's acquisition of Ouro is structurally a China-origin asset play dressed as a US biotech deal. Ouro held no proprietary research, it licensed the antibody from Keymed Biosciences and advanced it through early development. Gilead is not buying a pipeline team; it is buying access to IP generated in China's biotech ecosystem and buffered through a US corporate vehicle. That structure, Chinese origination, Western holding company, global acquirer, has become a deliberate routing mechanism to manage regulatory and geopolitical friction, and Gilead's willingness to pay $2.18B for it signals the mechanism is working. This is one of 12 M&A signals we have tracked in the last 90 days, though most of the related activity is cross-sector noise. Within biopharma and China-facing IP specifically, the Gilead-Ouro structure is consistent with a pattern of Western majors using intermediary vehicles to access Chinese biotech origination while avoiding direct cross-border licensing exposure. The relevant comparable pressure is the Tesla China divestiture signal, a data point showing that geopolitical risk calculus around China exposure is actively reshaping corporate structure across sectors. Companies operating in this corridor, Western pharma acquiring China-licensed assets through intermediary structures, face concentrated demand for cross-border regulatory and business development leadership: specifically, operators who can evaluate Chinese preclinical and clinical-stage assets, structure IP licensing across jurisdictions, and manage the regulatory timeline risk that comes when asset provenance and development geography diverge.

Market context: Against a Talent Market Index of 95.4 (Cool) (down 5.3 month-on-month), Asia is at rising (+3.1pts) on signal share.

Gilead Sciences: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 31 tracked companies; 0.1% of MitchelLake's Asia signal flow; 6 tracked across 216 days.

MitchelLake in this thematic

Also at Gilead Sciences →

More signals across Biotech & Pharma

M&A Activity · Asia

Torrent Pharmaceuticals →

NCLT (National Company Law Tribunal) approved Torrent Pharma acquisition of JB Chemicals; merger scheme to take effect after Registrar of Companies filing

Partnership · Asia

LOTTE Biologics →

LOTTE Biologics has signed a major commercial manufacturing agreement ahead of the completion of Songdo Plant 1, with full-scale commercial production slated to begin in 2027, supporting its dual-site strategy.

Partnership · Asia

Boehringer Ingelheim →

Boehringer Ingelheim's CEO says Korea is shifting from a sales market to a source of pharmaceutical innovation, with local biotech partnerships and clinical research expected to play a larger role in global drug development.

Partnership · Asia

WuXi Biologics →

Fresenius and WuXi Biologics announced a biosimilars development/manufacturing deal. Only the headline is available, so terms and scope are unknown.

Partnership · Asia

Bora Pharmaceuticals →

Bora Pharmaceuticals signed partnership with Insilico Medicine for AI drug discovery. Company launched group-wide AI in Manufacturing program (BORA AIM) to improve process efficiency across sites.

Product Launch · Asia

Biogen →

Biogen's monoclonal antibody felzartamab received first global approval in China for second-line multiple myeloma treatment, in combination with lenalidomide and dexamethasone.

Where this lands in our work

Weekly briefing

Track companies like Gilead Sciences — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record